Since 2001, the Hexacath clinical programme has enrolled thousands of patients internationally and has established the proven efficacy and safety of the Titanium Nitride Oxide coated stents in various population subsets such as Acute Coronary Syndrome patients, small vessels or diabetics. Randomized studies have demonstrated the superiority of this technology versus the first generation DES and its non inferiority versus the most recent DES generations with a trend towards higher safety as soon as 18 months after implantation. At last, Titanium Nitride Oxide Bio Active Stents require only a short term dual anti platelet treatment post stenting.
A prospective randomised comparison of titanium-nitride- oxide-coated ...
The journal of Invasive Cardiology
Gender-Based Analysis of the 3-Year Outcome of Bioactive Stents Versus...
Stent strut coverage of titanium-nitride-oxide coated stent compared t...
Elsevier Masson France
French Ministry of Health prospective multicentre study using bio-acti...
Titan 2 : a new breakthrough in interventional cardiology...